IRTC - iRhythm Technologies, Inc.
SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that the company will be participating in the following investor conferences.
iRhythm Technologies NASDAQ: IRTC executives said the company is seeing continued business momentum after a favorable Medicare coverage update, a stronger-than-expected first quarter and progress on several product and margin initiatives.
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The consensus price target hints at a 57.2% upside potential for IRHYTHM HLDGS (IRTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
iRhythm narrows Q1 losses, lifts 2026 outlook and posts 25.7% revenue growth as strong demand and margin gains drive momentum.
iRhythm Holdings, Inc. (IRTC) Q1 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.95 per share a year ago.
SAN FRANCISCO, April 30, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2026.
SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2026 Health Care Conference. iRhythm's management is scheduled to present on Wednesday, May 13, 2026, 9:20 a.m.
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio ® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations. 1-2 Findings raise important considerations for post-ablation anticoagulation decisions based on prior studies such as the OCEAN trial that relied on short-duration (24–48-hour) monitoring, as these data show this approach would miss AF recurrence in 26% of patients.
SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2026 after the close of trading on Thursday, April 30, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.
MSP Recovery (NASDAQ: MSPR - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Profitability This table compares MSP Recovery and iRhythm
iRhythm rides strong volume growth, AI-driven innovation and primary care expansion, but reimbursement pressure and rising competition cloud the outlook.
Data presented at ACC.26 demonstrate a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio ® ambulatory ECG portfolio. 1,2 Chief Medical Officer Mintu Turakhia, MD, MS, delivered the 57th Annual Louis F.
Assenagon Asset Management S.A. grew its stake in iRhythm Technologies (NASDAQ: IRTC) by 189.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 225,205 shares of the company's stock after buying an additional 147,329 shares during the quarter. Assenagon Asset
RTW Investments acquired 1,181,990 IRTC shares during Q4 2025, with an estimated position value of $210 million based on the 13F reported at quarter-end. The position represents 2.1% of RTW's 13F reportable AUM.
Cinctive Capital Management LP acquired a new stake in shares of iRhythm Technologies (NASDAQ: IRTC) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 28,044 shares of the company's stock, valued at approximately $4,823,000. Cinctive Capital Management LP owned about 0.09%